Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target ...

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $51 price target.

As part of the START Program, Neurogene will have opportunities for enhanced communications with the FDA, with the aim to furth...

HC Wainwright & Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:NGNE) with a Buy and lowers the price target fro...

Neurogene (NASDAQ:NGNE) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.14) by ...

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

These data were presented during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. 

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $55 price target.

Leerink Partners analyst Mani Foroohar initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces ...

The data show that the NGN-401 gene therapy candidate has been generally well-tolerated, and there have been no treatment-emerg...

William Blair analyst Sami Corwin initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating.